Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has a diagnosis of Ankylosing Spondylitis (AS) based on the Modified New York Criteria for AS (1984).~* Must have a radiograph of SI joints (AP Pelvis) documenting diagnosis of AS.~* Has active disease despite nonsteroidal anti-inflammatory drug (NSAID) therapy or intolerant to NSAIDs.~Exclusion Criteria:~* History of known or suspected complete ankylosis of the spine.~* History of allergies, intolerance or hypersensitivity to lactose or tofacitinib.~* History of any other rheumatic disease.~* Any subject with condition affecting oral drug absorption.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tofacitinib (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).